Regulatory, Compliance, and More.Efficacy and safety of Specific Conjugate Particle (SCP)- Doxorubicinin Patients with Recurrent High-Grade Gliomas, a Randomized Clinical Study(08-June-2017).
Introduction: Cervical cancer is the second most commonly occurring cancer in women, and it is responsible for 15% of all female malignancies. Metastatic cervical cancer occurs in 15-61% of cases, and available oncology therapies do not offer the [ Read More...]
Efficacy and safety of Specific Conjugate Particle (SCP)- Doxorubicin in Patients with Soft Tissue Sarcoma, a Randomized Clinical Study(10-April-2017).
Objective: Doxorubicin has been the mainstay of treatment for advanced STS. However, the conventional formulation of doxorubicin has not been used clinically, due to poor penetration of the natural physiologic barriers, poor water solubility and [ Read More...]
Randomized clinical study of SCP pacliataxel in patients with advanced cervical cancer.
Introduction: Cervical cancer is the second most commonly occurring cancer in women, and it is responsible for 15% of all female malignancies. Metastatic cervical cancer occurs in 15-61% of cases, and available oncology therapies do not offer the [ Read More...]